SLC6A3 and Parkinson disease: Recent publications from a multisite observational study in PD, the Parkinson’s Progression Markers Initiative (PPMI) suggest that quantified DAT binding may provide a valuable tool in assessing mechanisms from interventions designed to slow progression of the disease, especially early in the disease [40, 41, 42].